CBU
NVCR icon

CIBC Bancorp USA’s NovoCure NVCR Stock Holding History

CIBC Bancorp USA’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$140K Buy
+10,831
New +$145K ﹤0.01% 1318

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CIBC Bancorp USA's NVCR Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in NovoCure (NVCR) in Q3 2025: 10,831 shares worth $140K. The stake represents ﹤0.01% of the portfolio and ranks #1318 among its holdings.

244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • CIBC Bancorp USA held 10,831 shares of NovoCure worth $140K as of Q3 2025.
  • NovoCure was a new CIBC Bancorp USA position in Q3 2025.
  • NovoCure made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1318 holding.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.